Literature DB >> 34046626

Chemical modulation of Kv7 potassium channels.

Matteo Borgini1, Pravat Mondal1, Ruiting Liu1, Peter Wipf1.   

Abstract

The rising interest in Kv7 modulators originates from their ability to evoke fundamental electrophysiological perturbations in a tissue-specific manner. A large number of therapeutic applications are, in part, based on the clinical experience with two broad-spectrum Kv7 agonists, flupirtine and retigabine. Since precise molecular structures of human Kv7 channel subtypes in closed and open states have only very recently started to emerge, computational studies have traditionally been used to analyze binding modes and direct the development of more potent and selective Kv7 modulators with improved safety profiles. Herein, the synthetic and medicinal chemistry of small molecule modulators and the representative biological properties are summarized. Furthermore, new therapeutic applications supported by in vitro and in vivo assay data are suggested. This journal is © The Royal Society of Chemistry.

Entities:  

Year:  2021        PMID: 34046626      PMCID: PMC8128042          DOI: 10.1039/d0md00328j

Source DB:  PubMed          Journal:  RSC Med Chem        ISSN: 2632-8682


  376 in total

1.  Activation of KV7 channels stimulates vasodilatation of human placental chorionic plate arteries.

Authors:  T A Mills; S L Greenwood; G Devlin; Y Shweikh; M Robinson; E Cowley; C E Hayward; E C Cottrell; T Tropea; M F Brereton; W Dalby-Brown; M Wareing
Journal:  Placenta       Date:  2015-03-21       Impact factor: 3.481

Review 2.  Have there been improvements in Alzheimer's disease drug discovery over the past 5 years?

Authors:  Ramón Cacabelos
Journal:  Expert Opin Drug Discov       Date:  2018-04-01       Impact factor: 6.098

3.  Differential activation of vascular smooth muscle Kv7.4, Kv7.5, and Kv7.4/7.5 channels by ML213 and ICA-069673.

Authors:  Lyubov I Brueggemann; Jennifer M Haick; Leanne L Cribbs; Kenneth L Byron
Journal:  Mol Pharmacol       Date:  2014-06-18       Impact factor: 4.436

Review 4.  Potassium channel genes and benign familial neonatal epilepsy.

Authors:  Snezana Maljevic; Holger Lerche
Journal:  Prog Brain Res       Date:  2014       Impact factor: 2.453

5.  A carboxy-terminal inter-helix linker as the site of phosphatidylinositol 4,5-bisphosphate action on Kv7 (M-type) K+ channels.

Authors:  Ciria C Hernandez; Oleg Zaika; Mark S Shapiro
Journal:  J Gen Physiol       Date:  2008-09       Impact factor: 4.086

6.  Protein Kinase A-Mediated Suppression of the Slow Afterhyperpolarizing KCa3.1 Current in Temporal Lobe Epilepsy.

Authors:  Manindra Nath Tiwari; Sandesh Mohan; Yoav Biala; Yoel Yaari
Journal:  J Neurosci       Date:  2019-10-31       Impact factor: 6.167

7.  Acid-sensing ion channel 1 is involved in both axonal injury and demyelination in multiple sclerosis and its animal model.

Authors:  Sandra Vergo; Matthew J Craner; Ruth Etzensperger; Kathrine Attfield; Manuel A Friese; Jia Newcombe; Margaret Esiri; Lars Fugger
Journal:  Brain       Date:  2011-01-13       Impact factor: 13.501

8.  Differential contributions of Ca2+ -activated K+ channels and Na+ /K+ -ATPases to the generation of the slow afterhyperpolarization in CA1 pyramidal cells.

Authors:  Manindra Nath Tiwari; Sandesh Mohan; Yoav Biala; Yoel Yaari
Journal:  Hippocampus       Date:  2018-02-27       Impact factor: 3.899

9.  Mutant huntingtin enhances activation of dendritic Kv4 K+ channels in striatal spiny projection neurons.

Authors:  Luis Carrillo-Reid; Michelle Day; Zhong Xie; Alexandria E Melendez; Jyothisri Kondapalli; Joshua L Plotkin; David L Wokosin; Yu Chen; Geraldine J Kress; Michael Kaplitt; Ema Ilijic; Jaime N Guzman; C Savio Chan; D James Surmeier
Journal:  Elife       Date:  2019-04-24       Impact factor: 8.140

Review 10.  Neuropathic pain and Kv7 voltage-gated potassium channels: The potential role of Kv7 activators in the treatment of neuropathic pain.

Authors:  Alaa Abd-Elsayed; Markus Jackson; Steven L Gu; Kenneth Fiala; Jianguo Gu
Journal:  Mol Pain       Date:  2019 Jan-Dec       Impact factor: 3.395

View more
  6 in total

1.  Development of an automated screen for Kv7.2 potassium channels and discovery of a new agonist chemotype.

Authors:  Ciria C Hernandez; Rahilla A Tarfa; Jose Miguel I Limcaoco; Ruiting Liu; Pravat Mondal; Clare Hill; R Keith Duncan; Thanos Tzounopoulos; Corey R J Stephenson; Matthew J O'Meara; Peter Wipf
Journal:  Bioorg Med Chem Lett       Date:  2022-06-04       Impact factor: 2.940

2.  A potassium channel agonist protects hearing function and promotes outer hair cell survival in a mouse model for age-related hearing loss.

Authors:  Youssef Adel; Hubert Löwenheim; Barbara Peixoto Pinheiro; Marcus Müller; Michael Bös; Jamil Guezguez; Michael Burnet; Mara Tornincasa; Riccardo Rizzetto; Jean-Francois Rolland; Chiara Liberati; Stefan Lohmer
Journal:  Cell Death Dis       Date:  2022-07-11       Impact factor: 9.685

Review 3.  Behavior of KCNQ Channels in Neural Plasticity and Motor Disorders.

Authors:  Som P Singh; Matthew William; Mira Malavia; Xiang-Ping Chu
Journal:  Membranes (Basel)       Date:  2022-05-06

4.  Cannabidiol counters the effects of a dominant-negative pathogenic Kv7.2 variant.

Authors:  Xiaoqin Zhan; Chris Drummond-Main; Dylan Greening; Jinjing Yao; S W R Chen; J P Appendino; P Y Billie Au; Ray W Turner
Journal:  iScience       Date:  2022-09-06

5.  Clinically Relevant KCNQ1 Variants Causing KCNQ1-KCNE2 Gain-of-Function Affect the Ca2+ Sensitivity of the Channel.

Authors:  Christiane K Bauer; Tess Holling; Denise Horn; Mário Nôro Laço; Ebtesam Abdalla; Omneya Magdy Omar; Malik Alawi; Kerstin Kutsche
Journal:  Int J Mol Sci       Date:  2022-08-26       Impact factor: 6.208

6.  Antagonism of the Muscarinic Acetylcholine Type 1 Receptor Enhances Mitochondrial Membrane Potential and Expression of Respiratory Chain Components via AMPK in Human Neuroblastoma SH-SY5Y Cells and Primary Neurons.

Authors:  Farhana Naznin; T M Zaved Waise; Paul Fernyhough
Journal:  Mol Neurobiol       Date:  2022-08-25       Impact factor: 5.682

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.